Metastatic breast cancer treatment with the combination of PCS6422 and capecitabine (NGC-Cap) may increase the cancer-killing ...
Absence of Biallelic TCRγ Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia Chemotherapy-naive patients with GI tract cancers scheduled for ...
Machine Learning Model Integrating Computed Tomography Image–Derived Radiomics and Circulating miRNAs to Predict Residual Teratoma in Metastatic Nonseminoma Testicular Cancer Capecitabine, an oral ...
Onquality Pharmaceuticals LLC has received FDA clearance of its IND application for OQL-036, a potential prophylactic treatment for capecitabine-induced hand-foot syndrome (HFS).
SEATTLE, April 28, 2023 /PRNewswire/ -- OnQuality Pharmaceuticals ("OnQuality"), a targeted oncology supportive therapy company developing innovative medications to address unmet needs in ...
InvestorsHub on MSN
Processa Pharmaceuticals shares surge on encouraging cancer trial update
Shares of Processa Pharmaceuticals Inc. (NASDAQ:PCSA) jumped 23.8% on Wednesday after the company reported early Phase 2 ...
Processa anticipates completing enrollment of the final patient in the formal 20-patient interim analysis of Phase 2 safety and efficacy study by the end of the first quarter of 2026, in accordance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback